Author

Hilary R. Hernan

Observed names: H. Hernan, Hilary Hernan, Hilary R Hernan

Observed institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

OpenAlex ID: A5019192539

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer

2013 · Anne M. Traynor, Tracey L. Weigel, et al. · Lung Cancer · 64

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

2013 · Tien Hoang, Toby C. Campbell, et al. · Investigational New Drugs · 38

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

2012 · Noelle K. LoConte, Kyle D. Holen, et al. · Investigational New Drugs · 11

Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.

2013 · Anne M. Traynor, Glen E. Leverson, et al. · Journal of Clinical Oncology · 5

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

2011 · M. W. Jones, C. Zhang, et al. · Journal of Clinical Oncology · 4

Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies

2026 · David Braun, Nicholas Dana, et al. · medRxiv · 1

Abstract 3301: A sequential treatment strategy for ex vivo profiling of live tumor fragments that mitigates tumor heterogeneity and tissue scarcity from core needle biopsies to characterize response to immunotherapies

2025 · Christina Scribano, Pichet Adstamongkonkul, et al. · Cancer Research · 1

Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies

2026 · David Braun, Nicholas Dana, et al. · Cell Reports Medicine

Abstract 1389: Defining immune phenotypes of checkpoint inhibitor response in human live tumor fragments preserving the native tumor microenvironment.

2026 · Erika von Euw, Julie Zweng, et al. · Cancer Research

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

2025 · Nicholas Dana, Hilary R Hernan, et al. · Regular and Young Investigator Award Abstracts

ELEPHAS-01, ELEPHAS-02 and ELEPHAS-04: Multi-institutional observational prospective clinical trials to assess the accuracy of an ex vivo live tumor fragment platform for predicting immunotherapy response.

2025 · Hinco J. Gierman, Hilary Hernan, et al. · Journal of Clinical Oncology

Abstract 6555: A method for preparing tumor tissues for ex vivo culture that retains T cells within live tumor fragments while preserving tissue viability and T cell function

2025 · Michael Korrer, Christina Scribano, et al. · Cancer Research

529 Comparison of the clinical biomarkers dMMR, MSI-H and PD-L1 with cytokines secreted from anti-PD-1 treated human live tumor fragments on an ex vivo platform

2024 · Pichet Adstamongkonkul, Evan Flietner, et al. · Regular and Young Investigator Award Abstracts

Works count: 13

Citation count: 124

H-index: 4

I10-index: 3